Anew Medical, an early-stage biotechnology company, agreed to go public via a merger with Redwoods Acquisition, a publicly traded special purpose acquisition company, in a $94m deal. "ANEW is focused on developing disruptive new gene therapies to alleviate and/or reverse the progression of devastating neurodegenerative diseases. We are thrilled to be reaching this important milestone and we believe it will be incredibly beneficial for our mission as a company. The partnership with Redwoods as well as the listing on NASDAQ constitute an ideal pathway to raise additional capital and fund our strategic initiatives going forward. ANEW management looks forward to creating significant shareholder value over the next several years of product development and commercialization," Dr. Joseph Sinkule, ANEW CEO and Founder.